UTv Videos

"My predominant role as a genetic counselor is really to serve our patient population and help support our providers," says Brittany M. Szymaniak, PhD, CGC.

"Within the Inflation Reduction Act, there is a provision that will cap the out-of-pocket contribution for Medicare beneficiaries, dropping to $3250 in 2024, as well as $2,000 in 2025," says Brian Cortese.

"We did an additional study where we surveyed all of the medical students who applied to urology this year... 1 in 5 applicants took programs off their list because they were located in states where abortion is illegal," says Chloe E. Peters, MD.

"I can't speak for the FDA, but I would hope and anticipate that the results of this trial may lead to a modification of the label and the warning," says A. Michael Lincoff, MD.

"If you were to look at this paper and others that are coming out like it, it appears that disposable cystoscopy is going to be the future for us," said David D. Thiel, MD.

“After I finished my fellowship, I came straight back to Montefiore. I was very drawn to taking care of the patients in the Bronx,” says Amanda C. North, MD.

Hamid Emamekhoo, MD, explains his approach to discussing the ongoing cancer drug shortage with his patients with genitourinary cancers.

"We make the argument in our discussion of this paper that any discussion further on cost needs to include encounters," says David D. Thiel, MD.

"The principal finding was non inferiority," says A. Michael Lincoff, MD.

“I think the prostate cancer community has benefited a lot in the past several years with the advent of enhanced imaging tools to help us better stage patients with prostate cancer both at their initial diagnosis and if, unfortunately, they have a recurrence,” says Edward M. Schaeffer, MD, PhD.

"There are likely, based on their other results, going to be urologists not willing to move to those states, it's going to exacerbate shortages in care," says Chloe E. Peters, MD.

"41% of practicing urologists said that if Dobbs had happened when they were looking for their current position, they would have picked a different job," says Chloe E. Peters, MD.

A. Michael Lincoff, MD, shares the impetus for the TRAVERSE study.

"I would say that the take-home message of the study is that these immunosuppressive medications have alterations in the microbiology in a lot of these organs and a lot of these tumors," says Conor Driscoll, MD.

"The main advantage of the Lithovue Elite is that it allows for intrarenal and intraureteral pressure monitoring," says Ravi Munver, MD.

"Northwestern Madison's urology program has a very robust clinical research enterprise," says Edward M. Schaeffer, MD, PhD.

"Since 2021, there have been significant changes made to documentation and billing, where now our documentation can be more focused," says Jyoti Chouhan, DO, PharmD, FACS.

Anthony V. D’Amico, MD, PhD, discusses the choice between external beam radiation therapy and brachytherapy in patients with prostate cancer.

"The NCCN guidelines are unique in that they're almost constantly updated in real time," says Edward M. Schaeffer, MD, PhD.

"Once you've decided that this is important to you, a good place to start is to identify your pain points; pay attention to what annoys you and don't be complacent about it," says Sarah Hecht, MD.

"Prostate cancer showed a decreased risk, which we thought was very interesting, because it was the only cancer for which that signal existed, that there is possibly a protective effect of these medications," says Conor Driscoll, MD.

Karim Fizazi, MD, PhD, discusses safety data from the phase 3 TALAPRO-2 trial, which explored talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer.

"Catheters go in, [and] they come out within 2 to 3 days for my patients. Therefore, the perioperative period is very easy for patients, whereas radical surgery requires catheters for 7 to 10 days," says Kevin R. Basralian, MD.

"Since transforming the BPH market, Aquablation has as given a degree of confidence for the surgeon as well as for the patient," says Ravi Munver, MD.

"I think one of the key things is when we look at things like sensitivity and specificity, sensitivity is very much reliant on the incidence of a disease or the state of the disease," says Brian F. Chapin, MD.

Karim Fizazi, MD, PhD, highlights the TALAPRO-2 trial, which led to the FDA approval of talazoparib plus enzalutamide for patients with HRR gene–mutated metastatic castration-resistant prostate cancer.

"There are a lot of exciting data that are coming out, and, of course, a lot of physicians and physician-scientists [who] are interested in these questions, and we’re working on that," says Sophia C. Kamran, MD.